Pharma & Healthcare

Global Hepatic Encephalopathy Drugs Market Insights, Forecast to 2030

Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets & solutions) and injections.
The global Hepatic Encephalopathy Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Hepatic Encephalopathy Drugs include ASKA Pharmaceutical, Cosmo Pharmaceuticals, Bausch Health, Ferring Pharmaceuticals, Mallinckrodt, Umecrine Cognition, Norgine, Lupin and Kaleido Biosciences, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Hepatic Encephalopathy Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hepatic Encephalopathy Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Hepatic Encephalopathy Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hepatic Encephalopathy Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hepatic Encephalopathy Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Hepatic Encephalopathy Drugs sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Bausch Health
Ferring Pharmaceuticals
Mallinckrodt
Umecrine Cognition
Norgine
Lupin
Kaleido Biosciences
Kannalife Sciences
Segment by Type
Injection
Oral
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Hepatic Encephalopathy Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Hepatic Encephalopathy Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatic Encephalopathy Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Hepatic Encephalopathy Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Injection
1.2.3 Oral
1.3 Market by Application
1.3.1 Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts 2019-2030
2.2 Global Hepatic Encephalopathy Drugs Revenue by Region
2.2.1 Global Hepatic Encephalopathy Drugs Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Hepatic Encephalopathy Drugs Revenue by Region (2019-2024)
2.2.3 Global Hepatic Encephalopathy Drugs Revenue by Region (2025-2030)
2.2.4 Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2019-2030)
2.3 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts 2019-2030
2.4 Global Hepatic Encephalopathy Drugs Sales by Region
2.4.1 Global Hepatic Encephalopathy Drugs Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Hepatic Encephalopathy Drugs Sales by Region (2019-2024)
2.4.3 Global Hepatic Encephalopathy Drugs Sales by Region (2025-2030)
2.4.4 Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Hepatic Encephalopathy Drugs Sales by Manufacturers
3.1.1 Global Hepatic Encephalopathy Drugs Sales by Manufacturers (2019-2024)
3.1.2 Global Hepatic Encephalopathy Drugs Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hepatic Encephalopathy Drugs in 2023
3.2 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers
3.2.1 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (2019-2024)
3.2.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drugs Revenue in 2023
3.3 Global Key Players of Hepatic Encephalopathy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Hepatic Encephalopathy Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hepatic Encephalopathy Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hepatic Encephalopathy Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Hepatic Encephalopathy Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hepatic Encephalopathy Drugs Sales by Type
4.1.1 Global Hepatic Encephalopathy Drugs Historical Sales by Type (2019-2024)
4.1.2 Global Hepatic Encephalopathy Drugs Forecasted Sales by Type (2025-2030)
4.1.3 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
4.2 Global Hepatic Encephalopathy Drugs Revenue by Type
4.2.1 Global Hepatic Encephalopathy Drugs Historical Revenue by Type (2019-2024)
4.2.2 Global Hepatic Encephalopathy Drugs Forecasted Revenue by Type (2025-2030)
4.2.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Hepatic Encephalopathy Drugs Price by Type
4.3.1 Global Hepatic Encephalopathy Drugs Price by Type (2019-2024)
4.3.2 Global Hepatic Encephalopathy Drugs Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Hepatic Encephalopathy Drugs Sales by Application
5.1.1 Global Hepatic Encephalopathy Drugs Historical Sales by Application (2019-2024)
5.1.2 Global Hepatic Encephalopathy Drugs Forecasted Sales by Application (2025-2030)
5.1.3 Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
5.2 Global Hepatic Encephalopathy Drugs Revenue by Application
5.2.1 Global Hepatic Encephalopathy Drugs Historical Revenue by Application (2019-2024)
5.2.2 Global Hepatic Encephalopathy Drugs Forecasted Revenue by Application (2025-2030)
5.2.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Hepatic Encephalopathy Drugs Price by Application
5.3.1 Global Hepatic Encephalopathy Drugs Price by Application (2019-2024)
5.3.2 Global Hepatic Encephalopathy Drugs Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Hepatic Encephalopathy Drugs Market Size by Type
6.1.1 US & Canada Hepatic Encephalopathy Drugs Sales by Type (2019-2030)
6.1.2 US & Canada Hepatic Encephalopathy Drugs Revenue by Type (2019-2030)
6.2 US & Canada Hepatic Encephalopathy Drugs Market Size by Application
6.2.1 US & Canada Hepatic Encephalopathy Drugs Sales by Application (2019-2030)
6.2.2 US & Canada Hepatic Encephalopathy Drugs Revenue by Application (2019-2030)
6.3 US & Canada Hepatic Encephalopathy Drugs Market Size by Country
6.3.1 US & Canada Hepatic Encephalopathy Drugs Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Hepatic Encephalopathy Drugs Sales by Country (2019-2030)
6.3.3 US & Canada Hepatic Encephalopathy Drugs Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Hepatic Encephalopathy Drugs Market Size by Type
7.1.1 Europe Hepatic Encephalopathy Drugs Sales by Type (2019-2030)
7.1.2 Europe Hepatic Encephalopathy Drugs Revenue by Type (2019-2030)
7.2 Europe Hepatic Encephalopathy Drugs Market Size by Application
7.2.1 Europe Hepatic Encephalopathy Drugs Sales by Application (2019-2030)
7.2.2 Europe Hepatic Encephalopathy Drugs Revenue by Application (2019-2030)
7.3 Europe Hepatic Encephalopathy Drugs Market Size by Country
7.3.1 Europe Hepatic Encephalopathy Drugs Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Hepatic Encephalopathy Drugs Sales by Country (2019-2030)
7.3.3 Europe Hepatic Encephalopathy Drugs Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Hepatic Encephalopathy Drugs Market Size
8.1.1 China Hepatic Encephalopathy Drugs Sales (2019-2030)
8.1.2 China Hepatic Encephalopathy Drugs Revenue (2019-2030)
8.2 China Hepatic Encephalopathy Drugs Market Size by Application
8.2.1 China Hepatic Encephalopathy Drugs Sales by Application (2019-2030)
8.2.2 China Hepatic Encephalopathy Drugs Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Hepatic Encephalopathy Drugs Market Size by Type
9.1.1 Asia Hepatic Encephalopathy Drugs Sales by Type (2019-2030)
9.1.2 Asia Hepatic Encephalopathy Drugs Revenue by Type (2019-2030)
9.2 Asia Hepatic Encephalopathy Drugs Market Size by Application
9.2.1 Asia Hepatic Encephalopathy Drugs Sales by Application (2019-2030)
9.2.2 Asia Hepatic Encephalopathy Drugs Revenue by Application (2019-2030)
9.3 Asia Hepatic Encephalopathy Drugs Sales by Region
9.3.1 Asia Hepatic Encephalopathy Drugs Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Hepatic Encephalopathy Drugs Revenue by Region (2019-2030)
9.3.3 Asia Hepatic Encephalopathy Drugs Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 ASKA Pharmaceutical
11.1.1 ASKA Pharmaceutical Company Information
11.1.2 ASKA Pharmaceutical Overview
11.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ASKA Pharmaceutical Recent Developments
11.2 Cosmo Pharmaceuticals
11.2.1 Cosmo Pharmaceuticals Company Information
11.2.2 Cosmo Pharmaceuticals Overview
11.2.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Cosmo Pharmaceuticals Recent Developments
11.3 Bausch Health
11.3.1 Bausch Health Company Information
11.3.2 Bausch Health Overview
11.3.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Bausch Health Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bausch Health Recent Developments
11.4 Ferring Pharmaceuticals
11.4.1 Ferring Pharmaceuticals Company Information
11.4.2 Ferring Pharmaceuticals Overview
11.4.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ferring Pharmaceuticals Recent Developments
11.5 Mallinckrodt
11.5.1 Mallinckrodt Company Information
11.5.2 Mallinckrodt Overview
11.5.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Mallinckrodt Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Mallinckrodt Recent Developments
11.6 Umecrine Cognition
11.6.1 Umecrine Cognition Company Information
11.6.2 Umecrine Cognition Overview
11.6.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Umecrine Cognition Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Umecrine Cognition Recent Developments
11.7 Norgine
11.7.1 Norgine Company Information
11.7.2 Norgine Overview
11.7.3 Norgine Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Norgine Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Norgine Recent Developments
11.8 Lupin
11.8.1 Lupin Company Information
11.8.2 Lupin Overview
11.8.3 Lupin Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Lupin Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Lupin Recent Developments
11.9 Kaleido Biosciences
11.9.1 Kaleido Biosciences Company Information
11.9.2 Kaleido Biosciences Overview
11.9.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Kaleido Biosciences Recent Developments
11.10 Kannalife Sciences
11.10.1 Kannalife Sciences Company Information
11.10.2 Kannalife Sciences Overview
11.10.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Kannalife Sciences Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Kannalife Sciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Hepatic Encephalopathy Drugs Industry Chain Analysis
12.2 Hepatic Encephalopathy Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hepatic Encephalopathy Drugs Production Mode & Process
12.4 Hepatic Encephalopathy Drugs Sales and Marketing
12.4.1 Hepatic Encephalopathy Drugs Sales Channels
12.4.2 Hepatic Encephalopathy Drugs Distributors
12.5 Hepatic Encephalopathy Drugs Customers
13 Market Dynamics
13.1 Hepatic Encephalopathy Drugs Industry Trends
13.2 Hepatic Encephalopathy Drugs Market Drivers
13.3 Hepatic Encephalopathy Drugs Market Challenges
13.4 Hepatic Encephalopathy Drugs Market Restraints
14 Key Findings in The Global Hepatic Encephalopathy Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Injection
Table 3. Major Manufacturers of Oral
Table 4. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 5. Global Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 6. Global Hepatic Encephalopathy Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 7. Global Hepatic Encephalopathy Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 8. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2019-2024)
Table 9. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2025-2030)
Table 10. Global Hepatic Encephalopathy Drugs Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 11. Global Hepatic Encephalopathy Drugs Sales by Region (2019-2024) & (MT)
Table 12. Global Hepatic Encephalopathy Drugs Sales by Region (2025-2030) & (MT)
Table 13. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2019-2024)
Table 14. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2025-2030)
Table 15. Global Hepatic Encephalopathy Drugs Sales by Manufacturers (2019-2024) & (MT)
Table 16. Global Hepatic Encephalopathy Drugs Sales Share by Manufacturers (2019-2024)
Table 17. Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 18. Global Hepatic Encephalopathy Drugs Revenue Share by Manufacturers (2019-2024)
Table 19. Global Key Players of Hepatic Encephalopathy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 20. Hepatic Encephalopathy Drugs Price by Manufacturers 2019-2024 (USD/Kg)
Table 21. Global Hepatic Encephalopathy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Hepatic Encephalopathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatic Encephalopathy Drugs as of 2023)
Table 23. Global Key Manufacturers of Hepatic Encephalopathy Drugs, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Hepatic Encephalopathy Drugs, Product Offered and Application
Table 25. Global Key Manufacturers of Hepatic Encephalopathy Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hepatic Encephalopathy Drugs Sales by Type (2019-2024) & (MT)
Table 28. Global Hepatic Encephalopathy Drugs Sales by Type (2025-2030) & (MT)
Table 29. Global Hepatic Encephalopathy Drugs Sales Share by Type (2019-2024)
Table 30. Global Hepatic Encephalopathy Drugs Sales Share by Type (2025-2030)
Table 31. Global Hepatic Encephalopathy Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 32. Global Hepatic Encephalopathy Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 33. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2019-2024)
Table 34. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2025-2030)
Table 35. Hepatic Encephalopathy Drugs Price by Type (2019-2024) & (USD/Kg)
Table 36. Global Hepatic Encephalopathy Drugs Price Forecast by Type (2025-2030) & (USD/Kg)
Table 37. Global Hepatic Encephalopathy Drugs Sales by Application (2019-2024) & (MT)
Table 38. Global Hepatic Encephalopathy Drugs Sales by Application (2025-2030) & (MT)
Table 39. Global Hepatic Encephalopathy Drugs Sales Share by Application (2019-2024)
Table 40. Global Hepatic Encephalopathy Drugs Sales Share by Application (2025-2030)
Table 41. Global Hepatic Encephalopathy Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 42. Global Hepatic Encephalopathy Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 43. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2019-2024)
Table 44. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2025-2030)
Table 45. Hepatic Encephalopathy Drugs Price by Application (2019-2024) & (USD/Kg)
Table 46. Global Hepatic Encephalopathy Drugs Price Forecast by Application (2025-2030) & (USD/Kg)
Table 47. US & Canada Hepatic Encephalopathy Drugs Sales by Type (2019-2024) & (MT)
Table 48. US & Canada Hepatic Encephalopathy Drugs Sales by Type (2025-2030) & (MT)
Table 49. US & Canada Hepatic Encephalopathy Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 50. US & Canada Hepatic Encephalopathy Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 51. US & Canada Hepatic Encephalopathy Drugs Sales by Application (2019-2024) & (MT)
Table 52. US & Canada Hepatic Encephalopathy Drugs Sales by Application (2025-2030) & (MT)
Table 53. US & Canada Hepatic Encephalopathy Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 54. US & Canada Hepatic Encephalopathy Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 55. US & Canada Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 56. US & Canada Hepatic Encephalopathy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 57. US & Canada Hepatic Encephalopathy Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 58. US & Canada Hepatic Encephalopathy Drugs Sales by Country (2019-2024) & (MT)
Table 59. US & Canada Hepatic Encephalopathy Drugs Sales by Country (2025-2030) & (MT)
Table 60. Europe Hepatic Encephalopathy Drugs Sales by Type (2019-2024) & (MT)
Table 61. Europe Hepatic Encephalopathy Drugs Sales by Type (2025-2030) & (MT)
Table 62. Europe Hepatic Encephalopathy Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 63. Europe Hepatic Encephalopathy Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 64. Europe Hepatic Encephalopathy Drugs Sales by Application (2019-2024) & (MT)
Table 65. Europe Hepatic Encephalopathy Drugs Sales by Application (2025-2030) & (MT)
Table 66. Europe Hepatic Encephalopathy Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 67. Europe Hepatic Encephalopathy Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 68. Europe Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 69. Europe Hepatic Encephalopathy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 70. Europe Hepatic Encephalopathy Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 71. Europe Hepatic Encephalopathy Drugs Sales by Country (2019-2024) & (MT)
Table 72. Europe Hepatic Encephalopathy Drugs Sales by Country (2025-2030) & (MT)
Table 73. China Hepatic Encephalopathy Drugs Sales by Type (2019-2024) & (MT)
Table 74. China Hepatic Encephalopathy Drugs Sales by Type (2025-2030) & (MT)
Table 75. China Hepatic Encephalopathy Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 76. China Hepatic Encephalopathy Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 77. China Hepatic Encephalopathy Drugs Sales by Application (2019-2024) & (MT)
Table 78. China Hepatic Encephalopathy Drugs Sales by Application (2025-2030) & (MT)
Table 79. China Hepatic Encephalopathy Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 80. China Hepatic Encephalopathy Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 81. Asia Hepatic Encephalopathy Drugs Sales by Type (2019-2024) & (MT)
Table 82. Asia Hepatic Encephalopathy Drugs Sales by Type (2025-2030) & (MT)
Table 83. Asia Hepatic Encephalopathy Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 84. Asia Hepatic Encephalopathy Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 85. Asia Hepatic Encephalopathy Drugs Sales by Application (2019-2024) & (MT)
Table 86. Asia Hepatic Encephalopathy Drugs Sales by Application (2025-2030) & (MT)
Table 87. Asia Hepatic Encephalopathy Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 88. Asia Hepatic Encephalopathy Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 89. Asia Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 90. Asia Hepatic Encephalopathy Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 91. Asia Hepatic Encephalopathy Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 92. Asia Hepatic Encephalopathy Drugs Sales by Region (2019-2024) & (MT)
Table 93. Asia Hepatic Encephalopathy Drugs Sales by Region (2025-2030) & (MT)
Table 94. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Type (2019-2024) & (MT)
Table 95. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Type (2025-2030) & (MT)
Table 96. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 98. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Application (2019-2024) & (MT)
Table 99. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Application (2025-2030) & (MT)
Table 100. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 102. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 103. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 105. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Country (2019-2024) & (MT)
Table 106. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Country (2025-2030) & (MT)
Table 107. ASKA Pharmaceutical Company Information
Table 108. ASKA Pharmaceutical Description and Major Businesses
Table 109. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 110. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. ASKA Pharmaceutical Recent Developments
Table 112. Cosmo Pharmaceuticals Company Information
Table 113. Cosmo Pharmaceuticals Description and Major Businesses
Table 114. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 115. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Cosmo Pharmaceuticals Recent Developments
Table 117. Bausch Health Company Information
Table 118. Bausch Health Description and Major Businesses
Table 119. Bausch Health Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 120. Bausch Health Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Bausch Health Recent Developments
Table 122. Ferring Pharmaceuticals Company Information
Table 123. Ferring Pharmaceuticals Description and Major Businesses
Table 124. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 125. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Ferring Pharmaceuticals Recent Developments
Table 127. Mallinckrodt Company Information
Table 128. Mallinckrodt Description and Major Businesses
Table 129. Mallinckrodt Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 130. Mallinckrodt Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Mallinckrodt Recent Developments
Table 132. Umecrine Cognition Company Information
Table 133. Umecrine Cognition Description and Major Businesses
Table 134. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 135. Umecrine Cognition Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Umecrine Cognition Recent Developments
Table 137. Norgine Company Information
Table 138. Norgine Description and Major Businesses
Table 139. Norgine Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 140. Norgine Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Norgine Recent Developments
Table 142. Lupin Company Information
Table 143. Lupin Description and Major Businesses
Table 144. Lupin Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 145. Lupin Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Lupin Recent Developments
Table 147. Kaleido Biosciences Company Information
Table 148. Kaleido Biosciences Description and Major Businesses
Table 149. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 150. Kaleido Biosciences Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Kaleido Biosciences Recent Developments
Table 152. Kannalife Sciences Company Information
Table 153. Kannalife Sciences Description and Major Businesses
Table 154. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 155. Kannalife Sciences Hepatic Encephalopathy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Kannalife Sciences Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Hepatic Encephalopathy Drugs Distributors List
Table 160. Hepatic Encephalopathy Drugs Customers List
Table 161. Hepatic Encephalopathy Drugs Market Trends
Table 162. Hepatic Encephalopathy Drugs Market Drivers
Table 163. Hepatic Encephalopathy Drugs Market Challenges
Table 164. Hepatic Encephalopathy Drugs Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatic Encephalopathy Drugs Product Picture
Figure 2. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Hepatic Encephalopathy Drugs Market Share by Type in 2023 & 2030
Figure 4. Injection Product Picture
Figure 5. Oral Product Picture
Figure 6. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global Hepatic Encephalopathy Drugs Market Share by Application in 2023 & 2030
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Hepatic Encephalopathy Drugs Report Years Considered
Figure 12. Global Hepatic Encephalopathy Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Hepatic Encephalopathy Drugs Revenue 2019-2030 (US$ Million)
Figure 14. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 15. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2019-2030)
Figure 16. Global Hepatic Encephalopathy Drugs Sales 2019-2030 ((MT)
Figure 17. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2019-2030)
Figure 18. US & Canada Hepatic Encephalopathy Drugs Sales YoY (2019-2030) & (MT)
Figure 19. US & Canada Hepatic Encephalopathy Drugs Revenue YoY (2019-2030) & (US$ Million)
Figure 20. Europe Hepatic Encephalopathy Drugs Sales YoY (2019-2030) & (MT)
Figure 21. Europe Hepatic Encephalopathy Drugs Revenue YoY (2019-2030) & (US$ Million)
Figure 22. China Hepatic Encephalopathy Drugs Sales YoY (2019-2030) & (MT)
Figure 23. China Hepatic Encephalopathy Drugs Revenue YoY (2019-2030) & (US$ Million)
Figure 24. Asia (excluding China) Hepatic Encephalopathy Drugs Sales YoY (2019-2030) & (MT)
Figure 25. Asia (excluding China) Hepatic Encephalopathy Drugs Revenue YoY (2019-2030) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales YoY (2019-2030) & (MT)
Figure 27. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue YoY (2019-2030) & (US$ Million)
Figure 28. The Hepatic Encephalopathy Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 29. The Top 5 and 10 Largest Manufacturers of Hepatic Encephalopathy Drugs in the World: Market Share by Hepatic Encephalopathy Drugs Revenue in 2023
Figure 30. Global Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 31. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
Figure 32. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
Figure 33. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
Figure 34. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
Figure 35. US & Canada Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
Figure 36. US & Canada Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
Figure 37. US & Canada Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
Figure 38. US & Canada Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
Figure 39. US & Canada Hepatic Encephalopathy Drugs Revenue Share by Country (2019-2030)
Figure 40. US & Canada Hepatic Encephalopathy Drugs Sales Share by Country (2019-2030)
Figure 41. U.S. Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 42. Canada Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 43. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
Figure 44. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
Figure 45. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
Figure 46. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
Figure 47. Europe Hepatic Encephalopathy Drugs Revenue Share by Country (2019-2030)
Figure 48. Europe Hepatic Encephalopathy Drugs Sales Share by Country (2019-2030)
Figure 49. Germany Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 50. France Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 51. U.K. Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 52. Italy Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 53. Russia Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 54. China Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
Figure 55. China Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
Figure 56. China Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
Figure 57. China Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
Figure 58. Asia Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
Figure 59. Asia Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
Figure 60. Asia Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
Figure 61. Asia Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
Figure 62. Asia Hepatic Encephalopathy Drugs Revenue Share by Region (2019-2030)
Figure 63. Asia Hepatic Encephalopathy Drugs Sales Share by Region (2019-2030)
Figure 64. Japan Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 65. South Korea Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 66. China Taiwan Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 67. Southeast Asia Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 68. India Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Market Share by Type (2019-2030)
Figure 70. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Market Share by Type (2019-2030)
Figure 71. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Market Share by Application (2019-2030)
Figure 72. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Market Share by Application (2019-2030)
Figure 73. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Share by Country (2019-2030)
Figure 74. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Share by Country (2019-2030)
Figure 75. Brazil Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 76. Mexico Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 77. Turkey Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 78. Israel Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 79. GCC Countries Hepatic Encephalopathy Drugs Revenue (2019-2030) & (US$ Million)
Figure 80. Hepatic Encephalopathy Drugs Value Chain
Figure 81. Hepatic Encephalopathy Drugs Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies